Anna L. Fracanzani

Beyond MASLD: cardiometabolic dysfunction across liver disease etiologies.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: August 09, 2026

Low lysosomal acid lipase activity is associated with histological progression of metabolic dysfunction-associated steatotic liver disease.

Journal: Hepatology international

Published: February 03, 2026

Biopsy-proven immune-mediated hepatitis after valoctocogene roxaparvovec.

Journal: Haematologica

Published: January 15, 2026

The I148M PNPLA3 Variant Forces Progressive Portal MASLD by Spatially Perturbing Metabolic Pathways Across Liver Zones.

Journal: International journal of molecular sciences

Published: December 23, 2025

Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with metabolic dysfunction-associated steatotic liver disease.

Journal: Annals of hepatology

Published: November 25, 2025

Diagnostic Accuracy of Noninvasive Tests for Metabolic Dysfunction-associated Steatotic Liver Disease Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: November 01, 2025

Diagnostic Accuracy of Noninvasive Tests for Metabolic Dysfunction-Associated Steatotic Liver Disease Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: November 01, 2025

Diagnostic Accuracy of Non-Invasive Tests for MASLD Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: November 01, 2025

Increased Adiposity and Dyslipidemia in Young Men Living with HIV Compared to Matched PrEP Users: A Cross-Sectional Study.

Journal: Advances in therapy

Published: October 22, 2025

Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross-sectional study.

Journal: Diabetes, obesity & metabolism

Published: September 05, 2025

Beyond MASLD: cardiometabolic dysfunction across liver disease etiologies.

Beyond MASLD: cardiometabolic dysfunction across liver disease etiologies.

Low lysosomal acid lipase activity is associated with histological progression of metabolic dysfunction-associated steatotic liver disease.

Low lysosomal acid lipase activity is associated with histological progression of metabolic dysfunction-associated steatotic liver disease.

Biopsy-proven immune-mediated hepatitis after valoctocogene roxaparvovec.

Biopsy-proven immune-mediated hepatitis after valoctocogene roxaparvovec.

The I148M PNPLA3 Variant Forces Progressive Portal MASLD by Spatially Perturbing Metabolic Pathways Across Liver Zones.

The I148M PNPLA3 Variant Forces Progressive Portal MASLD by Spatially Perturbing Metabolic Pathways Across Liver Zones.

Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with metabolic dysfunction-associated steatotic liver disease.

Fibulin-3 as a reliable biomarker of fibrosis in obese subjects with metabolic dysfunction-associated steatotic liver disease.

Diagnostic Accuracy of Noninvasive Tests for Metabolic Dysfunction-associated Steatotic Liver Disease Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study.

Diagnostic Accuracy of Noninvasive Tests for Metabolic Dysfunction-associated Steatotic Liver Disease Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study.

Diagnostic Accuracy of Noninvasive Tests for Metabolic Dysfunction-Associated Steatotic Liver Disease Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study.

Diagnostic Accuracy of Noninvasive Tests for Metabolic Dysfunction-Associated Steatotic Liver Disease Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study.

Diagnostic Accuracy of Non-Invasive Tests for MASLD Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study.

Diagnostic Accuracy of Non-Invasive Tests for MASLD Across Age, Type 2 Diabetes, and Obesity Subgroups: A Multinational Study.

Increased Adiposity and Dyslipidemia in Young Men Living with HIV Compared to Matched PrEP Users: A Cross-Sectional Study.

Increased Adiposity and Dyslipidemia in Young Men Living with HIV Compared to Matched PrEP Users: A Cross-Sectional Study.

Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross-sectional study.

Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross-sectional study.

Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study.

Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study.

Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study.

Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study.